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Background: Recent studies have demonstrated that long non-coding RNAs (lncRNAs) were present in the blood of cancer
patients and have shown great potential as powerful and non-invasive tumor markers. However, little is known about the
value of lncRNAs in the diagnosis of esophageal squamous cell carcinoma (ESCC). We hypothesized that ESCC-related
lncRNAs might be released into the circulation during tumor initiation and could be utilized to detect and monitor ESCC.
Methods: Ten lncRNAs (HOTAIR, AFAP1-AS1, POU3F3, HNF1A-AS1, 91H, PlncRNA1, SPRY4-IT1, ENST00000435885.1,
XLOC_013104 and ENST00000547963.1) which previously found to be differently expressed in esophageal cancer
were selected as candidate targets for subsequent circulating lncRNA assay. A four-stage exploratory study was
conducted to test the hypothesis: (1) optimization of detected method to accurately and reproducibly measure
ESCC-related lncRNAs in plasma and serum; (2) evaluation of the stability of circulating lncRNAs in human plasma
or serum; (3) exploration the origin of ESCC-related lncRNAs in vitro and in vivo; (4) evaluation the diagnostic
power of circulating lncRNAs for ESCC.
Results: ESCC-related lncRNAs were detectable and stable in plasma of cancer patients, and derived largely from ESCC
tumor cells. Furthermore, plasma levels of POU3F3, HNF1A-AS1 and SPRY4-IT1 were significantly higher in ESCC patients
compared with normal controls. By receiver operating characteristic curve (ROC) analysis, among the three lncRNAs
investigated, plasma POU3F3 provided the highest diagnostic performance for detection of ESCC (the area under the
ROC curve (AUC), 0.842; p < 0.001; sensitivity, 72.8%; specificity, 89.4%). Moreover, use of POU3F3 and SCCA in
combination could provide a more effective diagnosis performance (AUC, 0.926, p < 0.001, sensitivity, 85.7%; specificity,
81.4%). Most importantly, this combination was effective to detect ESCC at an early stage (80.8%).
Conclusions: Plasma POU3F3 could serve as a potential biomarker for diagnosis of ESCC, and the combination of
POU3F3 and SCCA was more efficient for ESCC detection, in particular for early tumor screening.
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Esophageal squamous cell carcinoma (ESCC) is one of the
most fatal malignancies in humans, causing more than
400000 deaths per year [1]. Patients trend to present with
dysphagia at an advanced stage, and the 5-year survival
rate is less than 15% [2]. Current biomarkers such as* Correspondence: cxf551101@sina.com
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unless otherwise stated.serum squamous cell carcinoma antigen (SCCA), carbo-
hydrate antigen (CA) 19–9, and carcinoembryonic antigen
(CEA) are the classic tumor markers commonly used in
the management of patients with ESCC. However, these
tumor markers, have limited utility in the early detection
of ESCC due to lack of sufficiently high diagnostic sensi-
tivity and specificity [3]. Although CYFRA 21–1 has been
reported to have the higher sensitivity for diagnosing
ESCC than the traditional tumor markers, the sensitivity
is less than 10% for early detection of ESCC [4]. Therefore,
the significance of exploration of new biomarkers withhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Results of using RefFinder to evaluate and screen




△△Ct method GAPDH HPRT1 β-actin TBP
BestKeeper GAPDH β-actin HPRT1 TBP
Normfinder GAPDH β-actin HPRT1 TBP
GeNorm GAPDH HPRT1 β-actin TBP
Recommended comprehensive ranking GAPDH HPRT1 β-actin TBP
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should be emphasized.
Long non-coding RNAs (also known as lncRNAs),
which are longer than 200 bases with lack of protein-
coding capability, play critical roles in tumor initiation,
progression and metastasis by modulating oncogenic
and tumor-suppressing pathways [5,6]. Previous studies
have proved that lncRNAs are frequently dysregulated
expression in different kinds of tumors, including ESCC
[7]. The aberrant expression of lncRNAs have been re-
ported to serve as potential diagnostic or prognostic
biomarkers for many human malignancies such as
breast, lung, liver, and colon cancers [8-11]. Although
these lncRNAs have shown great promise as a new kind
of tumor markers, they cannot be used for clinical
screening purposes because of difficulty in getting biop-
sies of tissue from patients suspected to be ESCC.
Circulating RNA in plasma or serum has been an emer-
ging field for noninvasive diagnostic applications [12].
More recently, MicroRNAs (miRNAs) have been detected
in human peripheral blood, being remarkably stable in
spite of the high amounts of endogenous ribonuclease in
the blood of cancer patients [13]. Moreover, several clinical
trials have been approved by the FDA to assess the value of
serum miRNAs in cancer diagnosis (http://clinicaltrials.
gov) [14]. At present, several lncRNAs have been char-
acterized as potential tumor markers in human fluids.
For example, MALAT1 was found to be significantly up-
regulated in plasma of prostate cancer patients, and could
be used to discriminate cancer patients from healthy con-
trols [6,15]. In gastric cancer patients, plasma AA174084
levels dropped markedly on day 15 after surgery com-
pared with preoperative levels and were associated with
invasion and lymphatic metastasis [6,15]. However, to
our knowledge to date, no study has been performed re-
garding the circulating lncRNAs for early detection of
ESCC patients.
In the present study, 10 lncRNAs (HOTAIR, AFAP1-
AS1, POU3F3, HNF1A-AS1, 91H, PlncRNA1, SPRY4-IT1,
ENST00000435885.1, XLOC_013104 and ENST0000054
7963.1) that were previously reported with deregulated
expression in esophageal cancer were selected as candi-
date diagnostic makers [16-23]. They were examined in
tissues and plasma, and their potential use as tumor
markers for ESCC detection were evaluated. We hypoth-
esized that these ESCC-related lncRNAs might be re-
leased into the circulation during ESCC initiation and
could be utilized to detect and monitor ESCC. To test
the hypothesis, the following crucial questions need to
be addressed: 1) the stability of circulating lncRNAs in
plasma and serum, 2) the relationship between tumor
tissue lncRNAs and circulating lncRNAs, 3) and the
source of circulating lncRNAs (from cancer cells or from
normal blood cells).Results
Evaluation and screening of candidate endogenous control
In order to evaluate and screen the optimal endogenous
control for lncRNAs analysis of tissues and cells, the can-
didate reference genes (GAPDH, TBP, β-actin and HPRT1)
were measured in 21-pair ESCC tumor tissues and adja-
cent normal tissues. The raw Ct values were provided in
the supporting information (Additional file 1: Table S1).
Finally, through four common algorithms (Normfinder,
geNorm, BestKeeper, and the Comparative △△Ct method)
which were described elsewhere in details [24], GAPDH
was identified as the most stable endogenous control for
tissues lncRNAs analysis (Table 1).
However, for the early stage of circulating lncRNAs
study, no consensus exists on the use of endogenous
control for detection the lncRNAs in plasma. GAPDH,
which was reported to be stably expressed in plasma and
was selected as internal control in plasma by others be-
fore [15], was regarded as an ideal internal control for
plasma assay. Therefore, GAPDH expression was mea-
sured in 270 plasma samples (147cases and 123controls).
Results revealed that GAPDH level was stable in human
plasma and was not affected by age, sex, and pathology
(Additional file 2: Table S2).
Selection and detection of ESCC-related lncRNAs
On the basis of previous study, 10 lncRNAs (HOTAIR,
AFAP1-AS1, POU3F3, HNF1A-AS1, PlncRNA1, SPRY4-
IT1, ENST00000435885.1, ENST00000547963.1, 91H and
XLOC_013104) which have been reported to be differently
expressed in esophageal cancer were selected in the
present study. All the lncRNAs were then subjected to
qPCR validation, which was performed in 48 pairs of
ESCC tumor tissues and adjacent normal tissues. Among
them, HOTAIR, AFAP1-AS1, POU3F3, HNF1A-AS1,
PlncRNA1, SPRY4-IT1, ENST00000435885.1 and ENST00
000547963.1 were significantly higher in most of ESCC
tumor tissues compared with paired adjacent normal
tissues (Figure 1). However, expression of 91H and
XLOC_013104 did not show any significantly different
expression between the two groups and therefore were
ruled out in the subsequent study (Figure 1).
Figure 1 Validation of ESCC-related lncRNAs expression in ESCC tissues. △Ct method was used to calculate lncRNA expression, which was
normalized to GAPDH, and smaller ΔCt value indicated higher expression. Horizontal lines inside the box plots represent the median, boxes
represent the interquartile range, and error bars represent 97.5th and 2.5th percentiles. *P < 0.05.
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The detection of lncRNAs from plasma or serum with
sufficient sensitivity is a prerequisite of developing cir-
culating lncRNAs-based tumor markers. Therefore,
optimization of extraction method was very important
(detailed in Additional file 3: Text S1).
To explore whether these ESCC-related lncRNAs
could reach the circulation at levels sufficient to be de-
tectable, qPCR was then used to examine expression of
selected 8 lncRNAs in 48 plasma samples (24 clinical
samples and 24 normal controls). Of these lncRNAs, as
shown in Figure 2A-C, the levels of POU3F3 (p < 0.001),
HNF1A-AS1 (p < 0.001) and SPRY4-IT1 (p < 0.001) were
significantly higher in ESCC patients comparing with
normal controls. Moreover, to make sure whether these
lncRNAs were present in plasma, the qPCR products
were further validated by using traditional Sanger-based
method. As expected, their sequences were identical to
those derived from POU3F3, HNF1A-AS1 and SPRY4-
IT1 (Additional file 4: Figure S1). The results indicated
that ESCC-related lncRNAs could enter into the circula-
tion and their differentiate expression in plasma could
be used as diagnostic markers for ESCC. However,
PlncRNA1, HOTAIR and ENST00000547963.1 had a de-
tection rate of less than 60% in both ESCC plasma sam-
ples and normal controls, and therefore were excluded.
In addition, ENST00000435885 (p = 0.386) and AFAP1-
AS1 (p = 0.232) were also excluded because there wereno significant differences in their expressions between
the two groups (Additional file 5: Figure S2).Stability of ESCC-related lncRNAs in human plasma
To determine the stability of lncRNAs in plasma, given
that this is a crucial prerequisite for utility as tumor
markers, plasma samples were left under harsh condi-
tions including incubation at room temperature for 0, 6,
and 24 h, repeated freeze-thaw cycles, or low/high pH,
respectively. A total of 12 ESCC plasma samples were
assessed, and they were divided into three portions. At
room temperature, the levels of POU3F3, HNF1A-AS1
and SPRY4-IT1 were not significantly altered from 0 h
to 6 h, but then slightly decreased at 24 h when com-
pared with 6 h (Figure 3A). The stability of plasma
lncRNAs was treated with strong acid, strong base, or 10
multiple freeze-thaw cycles, respectively, for further val-
idation. As shown in Figure 3B and C, lncRNAs in
treated plasma remained stable compared to plasma not
treated Given that circulating lncRNA has been thought
to be unstable, because of the existence of the endogen-
ous RNase in blood. Three additional ESCC plasma sam-
ples were incubated with RNase A for 3 h at room
temperature to determine whether lncRNAs could be
degradated. Results indicated that RNase A had hardly
any effect on plasma level of POU3F3, HNF1A-AS1 and
SPRY4-IT1 (Figure 3D).
Figure 2 ESCC-related lncRNAs were detectable in plasma of
tumor patients and normal control. (A-C) Plasma levels of POU3F3
(A), HNF1A-AS1 (B), and SPRY4-IT1 (C) were measured in 24 clinical
samples and 24 cancer free controls. Horizontal bars indicate median
and interquartile range. Circulating lncRNAs expressions were
calculated using △Ct method. Statistical differences were analyzed
using Mann–Whitney test. *p < 0.001.
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and serum
To test whether there was a relationship between plasma
and serum lncRNAs level, POU3F3, HNF1A-AS1 and
SPRY4-IT1 were measured in EDTA-plasma samples and
clotted blood from the same individuals at the same blood
draw. As shown in Figure 4, measurements obtained from
plasma and serum were strongly correlated for POU3F3
(r = 0.833, mean differences = −0.71 ± 0.75, Figure 4A),
HNF1A-AS1 (r = 0.771, mean differences = −0.55 ± 1.12,Figure 4B) and SPRY4-IT1 (r = 0.724, mean differences =
−1.07 ± 0.95, Figure 4C), respectively. The results suggested
that serum and plasma samples were both acceptable for
evaluation of lncRNAs as blood-based tumor markers.
Origin of ESCC-related lncRNAs in plasma
To further test the hypothesis that plasma lncRNAs
were primarily released or leaked from the tumor cells.
Five independent experiments were carried out to deter-
mine the source of ESCC-related lncRNAs in plasma.
In the first experiment, qPCR was used to measure the
POU3F3, HNF1A-AS1 and SPRY4-IT1 expression in dif-
ferent five esophageal cell lines (including four ESCC
cells: KYSE30, KYSE70, KYSE450, and Eca 109, and one
normal human esophageal epithelial cell line: HET-1A),
and each cell culture medium which was incubated for
1, 2, and 3d (Figure 5A and B). Data presented in
Figure 5B indicated that ESCC-related lncRNAs could
enter into the cell culture medium at a detectable level
and were steadily increased among the three incubation
time points in the all four ESCC cell lines; however, no
significant changes were observed in normal esophageal
epithelial cell culture medium.
In the second experiment, a mouse ESCC xenograft
model system was established to further investigate
whether ESCC-related lncRNAs could enter the circula-
tion at a measurable level. Blood samples were collected
4 weeks after implanting the KYSE30 cells or PBS, and
the blood processing and RNA isolation were the same
as those described for human plasma. Then the qPCR
results demonstrated that the presence of tumor was the
major contributor to plasma lncRNAs (Figure 5C).
In the third experiment, qPCR was used to measure the
ESCC-related lncRNAs expression in 24 ESCC tumor tis-
sues and paired plasma samples, and then correlation of
the levels of ESCC-related lncRNAs between the two
groups was analyzed. As shown in Figure 5D, a moderate
significant correlation was observed for POU3F3 (r =
0.497, p = 0.001), HNF1A-AS1 (r = 0.538, p < 0.001), and
SPRY4-IT1 ((r = 0.633, p < 0.001), respectively, which was
consistent with our previous hypothesis.
Since circulating lncRNAs were primarily released or
leaked from tumor cells, they would presumably revert to
normal after the tumor has been resected. To test this hy-
pothesis, the fourth experiment was carried out to investi-
gate the differences in ESCC-related lncRNAs in plasma
before and 14d after surgery. As expected, plasma levels of
POU3F3 (p < 0.001, Wilcoxon test) HNF1A-AS1 (p =
0.002, Wilcoxon test) and SPRY4-IT1 (p = 0.001, Wilcoxon
test) were markedly declined 14d after surgical treatment
compared with before surgery (Figure 5E).
In addition, previous studies reported that some circu-
lating RNAs could derive from the blood cells [25].
Therefore, the fifth experiment with delayed blood
Figure 3 Stability of plasma ESCC-related lncRNAs. POU3F3, HNF1A-AS1, and SPRY4-IT1 shown no significant degradation when plasma was
treated with prolonged room temperature incubation time (A), or multiple freeze-thaw cycles (B), or low (pH = 1) or high (pH = 13) pH solution
(C), or RNase A digestion (D). Data presented as raw Ct value, and each bars represented the mean (SD) (n = 3).
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ther clarify the origin of circulating ESCC-related
lncRNAs. A total of 12 EDTA-blood samples collected
from healthy participants were used in this part of study.
Four blood samples were incubated at room temperature
for 0, 6, 12, and 24 h, and the second 4 blood samples
were left at 4°C for 0, 6, 12, and 24 h. The last 4 blood
samples were treated as the same as the first part, but
the collected plasma was filtered through a 0.22 μm fil-
ter. After the treatment, plasma was then collected for
RNA isolation. The results showed that, at room
temperature, POU3F3, HNF1A-AS1 and SPRY4-IT1 ex-
pression in the unfiltered plasma was slightly increased
at 6 h compared to 0 h, but then significantly declined
at 24 h compared to 6 h (Figure 5F). However, no sig-
nificant differences were observed when the EDTA-
blood was left at 4°C or for the filtered plasma (Additional
file 6: Figure S3).Correlation between plasma lncRNAs and
clinicopathological characteristics
To further determine whether the three lncRNAs levels in
ESCC plasma were associated with specific clinicopatho-
logic parameters, such as gender, tumor size, histologic
grade, smoking status, alcohol consumption, TNM stage,
and clinical stage. POU3F3, HNF1A-AS1 and SPRY4-
IT1 expression levels were measured in all 147 ESCCpatients; however, there was no significant association
between plasma lncRNAs and clinicopathological pa-
rameters (Additional file 7: Table S3).Evaluation of lncRNAs in plasma as novel tumor markers
for ESCC
To investigate the characteristics of the three ESCC-
related lncRNAs as potential tumor markers of ESCC, Re-
ceiver operating characteristics (ROC) curves and the area
under the ROC curves (AUC) were performed on data
from all subjects, including 147 ESCC patients and 123
healthy donors. The ROC curves illustrated strong separ-
ation between the ESCC patients and control group, with
an AUC of 0.842 (95% CI: 0.794 – 0.890; p < 0.001) for
POU3F3, 0.781 (95% CI: 0.727 – 0.835: p < 0.001) for
HNF1A-AS1, and 0.800 (95% CI: 0.748 – 0.853: p < 0.001)
for SPRY4-IT1, respectively, compared with classic tumor
marker SCCA (ng/ml) with an AUC of 0.784 (95% CI:
0.727 – 0.841; p < 0.001) (Figure 6). Moreover, plasma
level of POU3F3 could discriminate ESCC from normal
controls with 72.8% sensitivity and 89.4% specificity, al-
though the levels of HNF1A-AS1 and SPRY4-IT1 in
plasma were less sensitive (32.7% and 48.2%) for ESCC de-
tection. Therefore, of the three lncRNAs in this analysis,
POU3F3 provided the highest diagnostic power for the de-
tection of ESCC, suggesting that plasma POU3F3 could
serve as a promising tumor marker for ESCC diagnosis.
Figure 4 Correlation of ESCC-related lncRNAs expression between plasma and serum. Left panel, linear correlation plot of POU3F3 (A), HNF1A-AS1
(B) and SPRY4-IT1 (C) level from plasma (y-axis) versus from serum (x-axis). There was a high correlation comparing the indicated lncRNAs levels between
plasma and serum. Spearman’s rank analysis was used to identify the correlation of lncRNAs levels between plasma and serum. Right panel, Bland-Altman
plot of the difference between plasma and serum ESCC-related lncRNAs level (y-axis) versus their average (x-axis). Horizontal solid lines in the middle
represent the mean difference. Upper and lower solid lines represent the limits of agreement (95% confidence intervals).
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There is increasing evidence showing that combin-
ation several tumor markers could improve diagnostic
accuracy. In this study, we determined whether the
combination of POU3F3 and SCCA would provide a
more effective diagnosis performance for detection of
ESCC. As shown in Figure 7, by binary logistic regression,
combination of POU3F3 and SCCA yielded an AUC of
0.926 (95% CI: 0.896 – 0.955; p < 0.001), which was signifi-
cantly improved compared with SCCA (AUC= 0.784) or
lncRNA POU3F3 (AUC = 0.842) alone. The sensitivity,specificity, accuracy of SCCA, POU3F3, and the combin-
ation (SCCA + POU3F3) for distinguishing ESCC from
healthy controls were summarized in Table 2.
Tumor stage and performance of the combination of
POU3F3 and SCCA
The key aim of this work was to diagnose ESCC patients
at as early stage as possible at the time cancer therapy
could be more likely successful. Therefore, the diagnos-
tic positivity rate between different clinical stages was
then investigated. As shown in Table 3, in stage I, the
Figure 5 Origin of circulating lncRNAs. (A) Quantitative real time polymerase chain reaction (qPCR) was used to measure ESCC-related lncRNAs expression
in five esophageal cells. GAPDH was used as a normalization control. (B) ESCC-related lncRNAs could be secreted into the cell culture medium. Data presented
as relative lncRNAs fold change. (C) ESCC-related lncRNAs could enter into the circulation of xenograft-bearing mice. (D) Spearman’s rank correlation scatter plot
of ESCC-related lncRNAs levels in tumor samples and plasma. Data were presented as △Ct values normalized to GAPDH. (E) ESCC-related lncRNAs expressions
were significantly declined in post-operative samples compared with that in pre-operative samples. (F) Effect of delayed blood centrifugation on plasma ESCC-
related lncRNAs expressions. At room temperature, ESCC-related lncRNAs levels of unfiltered plasma was slightly increased from 0 h to 6 h, but then significantly
decreased at 24 h when compared to 6 h. *p<0.05.
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in combination was 26%, 69.2%, and 80.8%, respectively.
Discussion
Recently, it has been demonstrated that the cell-free nu-
cleic acids are detectable in plasma and serum of cancer
patients and therefore may be utilized as a tool for can-
cer diagnosis [26]. Although numerous studies have fo-
cused on miRNAs as potential tumor markers for cancer
diagnosis and prognosis prediction, the diagnostic utility
of plasma lncRNAs in ESCC has never been studied.
In the present study, the initial ESCC-related lncRNAs
screening was performed based on different expression
profiling between ESCC tumor samples and matched
normal samples that have been demonstrated in previ-
ous studies. All lncRNAs of interest were then subjected
to qPCR validation. Eight lncRNAs were identified and
then further measured their expression levels in plasma
from ESCC patients and healthy subjects. The results
demonstrated that the levels of POU3F3, HNF1A-AS1
and SPRY4-IT1 were significantly higher in plasma from
ESCC patients compared with normal controls, provid-
ing strong evidence that ESCC-related lncRNAs could
be released into the circulation and that their different
expression profiles in plasma could be used as diagnostic
markers for ESCC. Among the three lncRNAs, POU3F3provided the highest diagnostic power for detection of
ESCC (AUC = 0.842; sensitivity, 72.8%; and specificity,
89.4%), suggesting that plasma POU3F3 could serve as a
promising tumor marker for ESCC detection. Further-
more, use of POU3F3 and SCCA in combination could
provide a more powerful differential diagnosis between
ESCC patients and healthy controls than use of POU3F3
or SCCA alone. Therefore, both in combination could
be used as a diagnostic tool for screening apparently
healthy individuals. Most importantly, the results indi-
cated that plasma POU3F3 was more effective than
SCCA for early detection of ESCC (69.2% vs 26%), and
that the positivity rate of both in combination was sig-
nificantly improved compared with SCCA or POU3F3
alone. In addition, we also proved the mirVana PARIS
Kit (Ambion 1556, USA) approach as the most effective
RNA extraction method, and both plasma and serum
would be acceptable for evaluation of lncRNAs as blood-
based tumor markers. This is the first time to systemat-
ically characterize circulating lncRNAs in plasma as
diagnostic markers for ESCC.
Recently, many tumor markers such as SCCA, CEA,
CA19-9, MMP-9, IL-6, CYFRA 21–1, DKK-1, M-CSF,
MiR-18a, MiR-1246 and many other genes were evaluated
for ESCC diagnosis [3,27-30]. However, there was no suffi-
cient sensitivity and specificity for these biomarkers, even
Figure 6 Evaluation of plasma lncRNAs for detection of ESCC. Receiver operating characteristics (ROC) curves were drawn with the data of
plasma lncRNAs from 147 patients with ESCC and 123 healthy controls. (A-D) ROC-AUC for detecting ESCC from healthy controls (POU3F3, 0.842,
p < 0.001; HNF1A-AS1, 0.781, p < 0.001; SPRY4-IT1, 0.800, p < 0.001; SCCA, 0.784, p < 0.001).
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CEA and SCCA.Mealy K reported that the individual sen-
sitivities of CEA and SCCA for the diagnosis of ESCC
were about 28% and 32%, respectively [28]. Yamamoto K
study demonstrated that the sensitivity of CYFRA 21–1
was only 47.9%, although the specificity was 100% [31].
MMP-9 has been shown to have higher diagnostic sensi-
tivity of ESCC compared to SCCA, but its diagnostic per-
formance was poorer [31]. Serum MiR-1246 improved the
discriminatory power, but sensitivity and specificity were
lower [30,32]. This study was sought to find novel markers
that could improve early detection of ESCC. Our results
demonstrated that plasma lncRNA POU3F3 was a prom-
ising tumor marker, which effectively supplemented the
serum SCCA for ESCC detection.
In the past several years, qPCR has been considered to
be a reliable method for quantitative gene expression
due to its accuracy, sensitivity, specificity, reproducibility
and robustness [33]. However, to produce accurateresults in qPCR assays the use of robust normalization
strategy is important [34]. Generally, the use of reference
gene as endogenous controls is the most commonly
method for normalizing qPCR gene expression data.
Currently, several mathematical algorithms which are
specifically developed for reference gene evaluation and
selection deliver suitable reference genes with the lowest
variation and with high stability across the biological
samples. The four commonly used approaches are: (1)
NormFinder algorithm which is a statistical model that es-
timates the overall variation of gene expression for each
candidate reference gene and delivers a stability value. (2)
GeNorm. (3) BestKeeper, a Microsof Excel-based tool,
uses pair-wise correlation and (4) the comparative delta
Ct [35]. Therefore, in this study we paid special attention
on reference genes selection. All candidate reference genes
for ESCC tissue lncRNAs normalization were chosen
based on their stably expressed in different human tissues
or were once used in ESCC qPCR study. Finally through
Figure 7 ROC corves to compare the diagnostic performance of
SCCA, POU3F3, and a combination of SCCA and POU3F3, to
discriminate ESCC from normal controls. The combination of
SCCA and POU3F3 provided a more powerful differential diagnosis
compared with SCCA and POU3F3 alone (SCCA+ POU3F3, 0.926, p <
0.001; POU3F3, 0.842, p < 0.001; SCCA, 0.784, p < 0.001).
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normalization of tissue lncRNAs measurement because of
its best reference performance (Table 1). This was in
agreement with Li W [18], using GAPDH normalization
lncRNA POU3F3 expression in tissue samples of ESCC
patients. As there was no established endogenous control
for detection of plasma or serum lncRNAs, GAPDH was
selected as a potential reference gene. And we observed
that plasma GAPDH expression level was stable between
the ESCC group and normal control group and was not
affected by age, sex, and pathology. However, in the previ-
ous study by Ng EK et al. [36]. GAPDH seemed to be no
feasible reference gene because of its expression level in
HCC patients was significantly higher than those in health
individuals. One possible explanation was that different
diseases and selected primer pair was not the best choice
for measuring gene expression could influence the expres-
sion of GAPDH.
Circulating lncRNAs were thought to be unstable be-
cause of the high level of RNase activity in plasma, and
in cancer patients, increased plasma RNase has been de-
tected [12]. In the present study, we confirmed that cir-
culating lncRNAs were remarkably stable even when
treated directly with RNase A digestion. These findingsTable 2 Performance of SCCA, POU3F3, and both SCCA and P
participants
Sensitivity Specificity Accuracy Youden index
SCCA 59.2% 93.5% 74.8% 52.7%
POU3F3 72.8% 89.4% 80.3% 62.2%
SCCA + POU3F3 85.7% 81.4% 83.7% 67.1%
Abbreviations: SCCA squamous cell carcinoma antigen.were consistent with those in patients with prostate can-
cer [6]. However, the precise mechanism used to explain
why circulating lncRNAs are resistant to endogenous
RNase digestion remains largely unknown. One explan-
ation is that they are packaged in some kinds of micro-
particles, such as exosomes, microvesicles, apoptotic
bodies, and apoptotic microparticles [14,37]. Our results
of the blood-processing assay support this explanation.
Recently, it has been hypothesized that circulating RNAs
could be modified in certain ways, including methyla-
tion, adenylation, and uridylation which make them re-
sistant to RNase digestion [38]. Another possible
explanation is that lncRNAs often forms secondary
structures, and relatively more stable, which could facili-
tate their detection as free nucleic acids in body fluids
such as blood and urine [39]. The mechanism of resist-
ance of circulating lncRNAs to RNase deserves further
study. In the present study, we also demonstrated that
plasma lncRNAs were resistant to multiple freeze-thaw
cycles, strong acid and base treatment. However, when
plasma or unprocessed blood was subjected to extended
room temperature incubation, the concentrations of
lncRNAs were even more variable. Such artifactual fluc-
tuations in lncRNAs concentrations may be attributable
to two factors: the secreted lncRNA from necrotic and/
or apoptotic blood cells; the stability of original and the
newly secreted lncRNA [12]. Taking the unprocessed
EDTA-blood for instance (Figure 5F); an initial increase
in lncRNAs concentrations at 6 h may be the result of
the newly released lncRNAs from blood cells. After that,
the lncRNA concentrations started to decline which may
be attributable to the degradation of the newly secreted
lncRNAs. Based on the above results, we recommend
that the unprocessed EDTA-blood should be stored at 4°
C.
The release of nucleic acids into the blood is thought
to be associated with apoptosis and necrosis tumor cells
from the tumor microenvironments and is also the re-
sults of secretion [40,41]. In the previous study of circu-
lating lncRNA LIPCAR in heart failure patients from
Kumarswamy and his colleges, who suggested that a
good proportion of mitochondrial lncRNAs detected in
circulation might come from the heart [42]. On the con-
trary, Prichard et al. provided the pioneering evidence
that blood cells were the major contributor to theOU3F3 in the differential diagnosis ESCC from healthy
True positive True negative False-positive False-negative
87 115 8 60
107 110 13 40
126 100 23 21
Table 3 Performance of SCCA, POU3F3 and both SCCA and POU3F3 in the detection of different clinical stage ESCC
Clinical stage P (Pearson
Chi-square)I II III IV Total
SCCA 26% (7/26) 35.9% (14/39) 76.4% (39/51) 87.1% (27/31) 59.2% (87/147) 0.000
POU3F3 69.2% (18/26) 66.6% (26/39) 78.4% (40/51) 74.2% (23/31) 72.8% (107/147) 0.455
SCCA + POU3F3 80.8% (21/26) 76.9% (30/39) 90.2% (46/51) 93.5% (29/31) 85.7% (126/147) 0.147
P (combination vs. SCCA) 0.000 0.001 0.109 0.671 0.000
Abbreviations: SCCA squamous cell carcinoma antigen, statistic analysis, Pearson Chi-Square or Fisher’s Exact Test.
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http://www.molecular-cancer.com/content/14/1/3circulating miRNAs and that perturbations in blood cell
counts and hemolysis could alter plasma miRNAs levels
by up to 50-fold [25]. Another possible origin may be
that the circulating miRNAs of cancer patients were not
just a result of cancer but may actively contribute to
cancer defense, because the population of circulating
miRNAs correlated tightly with the immune response
[40]. Currently, there were three major hypotheses for
circulating miRNAs to enter into the circulation: energy-
free passive leakage of cellular miRNAs into circulation;
active and selective secretion of miRNAs in response to
various stimuli as microvesicle-free miRNAs; and active
secretion via cell-derived microvesicles [38]. These theor-
ies could also be utilized to explain the origin of circulat-
ing lncRNAs. In this study, we found that ESCC-related
lncRNAs could enter into the cell culture medium at a
measurable level. Furthermore, ESCC-related lncRNAs
were derived from tumor cells as evidenced with the
xenograft assay, the relationship of ESCC-related lncRNAs
levels between the tumor samples and plasma matched
for the same individuals, and the changes of plasma
ESCC-related lncRNAs concentrations between pre-Op
and post-Op. However, the delayed blood processing assay
suggested that the circulating lncRNAs could also be re-
leased from blood cells although their contribution was
minor. Therefore, to avoid the origin of lncRNAs from
blood cells, the unprocessed blood should be stored at 4°C
and further processed as soon as possible. In addition, the
stable levels of the three lncRNAs in the filtered plasma
could be used to explain why increased plasma lncRNAs
detected in unfiltered blood samples were largely from mi-
croparticles. Some patients, however, exhibited a different
pattern of lncRNAs expression, low expression in plasma
with high levels in ESCC tissues. At present, it was diffi-
cult to explain such phenomena; one possible hypothesis
for that phenomenon could be the heterogeneity of pri-
mary tumor. At present, the exact biological roles of circu-
lating lncRNAs in cancer patients remain unclear. Are
they merely molecular remnants of necrotic tumor cells
or do they play important roles in cell-to-cell communica-
tion? Obviously, more investigations will be needed to
solve the exciting questions.Limitation of the study
However, research limitations exist in our study, such as
modest sample size, relatively low sensitivity qPCR
method and failure in deep functional investigation. Fur-
ther studies focused on the biological role of plasma
lncRNAs are needed.
Conclusions
In summary, our results suggested that increased plasma
lncRNA POU3F3 can be used as ideal tumor biomarker
for ESCC detection, and that combination of POU3F3
and SCCA has a higher positive diagnostic rate of ESCC




Written informed consent was obtained from each partici-
pant prior to blood and tumor samples collection. All of
the clinical samples were obtained from Nanjing Medical
University Nanjing First Hospital (Nanjing, China) and
Huai’an First Hospital (Huai’an, China). The study proto-
col was approved by the Clinical Research Ethics Commit-
tee of Nanjing First Hospital and Huai’an First Hospital,
respectively.
Clinical samples and plasma preparation
In this study, 147 consecutive hospitalized patients who
had newly diagnosed with ESCC were selected from
Nanjing Medical University affiliated Nanjing Hospital
(n = 53) and Nanjing Medical University affiliated Huai’an
First Hospital (n = 94) between January 2013 and May
2014. All patients selected met the following inclusion cri-
teria: pathological examination confirmed primary ESCC
by available biopsy samples; and no anticancer treatments
were given before surgery. Summarized in Additional
file 8: Table S4 were the clinicopathological characteris-
tics of the 147 patients, including gender, age, tumor
size, CEA, SCCA, histologic grade, smoking status, alco-
hol consumption, TNM stage and clinical stage. The
tumors were staged according to the 7th edition of
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http://www.molecular-cancer.com/content/14/1/3tumor-node-metastasis (TNM) classification for esopha-
geal carcinoma (UICC, 2009) [43].
One hundred and twenty-three adult healthy volun-
teer donors were enrolled as a normal control group.
None of the donors have any esophageal disease or any
other types of malignancy, with information detailed in
Additional file 8: Table S4.
Fresh tumor tissues and paired adjacent normal tissues
were obtained from ESCC patients and were immedi-
ately frozen in liquid nitrogen and then stored at −80°C
until RNA extraction.
Peripheral blood from ESCC patients was drawn be-
fore and 14d after surgery. Up to 5 ml of blood was col-
lected from each subject in a K2EDTA plasma tube and
was processed within 1 h for plasma collection. For
serum collection, all blood samples were allowed to clot
at room temperature for a minimum of 30 min and a
maximum of 2 h. Cell and cellular components-free
plasma or serum was isolated from all blood samples
using a two-step centrifugation protocol (2000 g for
10 min at 4°C, 12000 g for 10 min at 4°C) to thoroughly
remove cellular nucleic acids. After separation, plasma
and serum samples were transferred to RNase DNase-
free tubes and stored at −80°C until total RNA extrac-
tion. Blood samples with hemolysis were excluded.
Cell culture
All cells were a generous gift from Dr. Zhi-Hua Liu, the
State Key Laboratory of Molecular Oncology, Cancer In-
stitute, Chinese Academy of Medical Sciences (Beijing,
China). Human KYSE30, KYSE70, KYSE450, Eca 109 and
HET-1A were cultured in RPMI medium 1640 (Invitro-
gen, Carlsbad, CA) containing 10% fetal bovine serum
(Gibco, Grand Island, NY) and 1% penicillin-streptomycin
at 37°C in 5% CO2. Cells were plated in 6-well plate at a
density of 2 × 105 per well, and then the medium was
switched to fresh RPMI-1640 ~ 12 h after plating. After in-
cubation for 3 days, the cells and the cell culture media
were separately collected for RNA isolation. The process-
ing of conditioned media was the same as that described
for plasma collection.
Xenograft experiments
The animal study was performed in accordance with the
NIH animal use guidelines to explore the source of cir-
culating lncRNAs. In brief, KYSE30 cells were collected
at exponential growing stage when they reached ~70%
confluence. About 1 × 106 cells in 50% matrigel were
injected subcutaneously into the flanks of the BALB/C
nude mice (n = 12). An equal number of mice were
injected with 100 μl of 50% matrigel in PBS as controls.
Four weeks after implantation, mice were anesthetized
and their blood was collected in EDTA tube using car-
diac puncture and processed for isolation of plasma.RNA isolation
RNA extraction from tissues and cultured cells was
performed using Trizol reagent (Invitrogen, Carlsbad,
CA, USA), whereas total RNA in plasma or cell culture
media was isolated by using mirVana PARIS Kit (Ambion
1556, USA). Detailed description of RNA extraction was
provided in Supporting Information (Additional file 9:
Table S5).Quantitative real-time PCR (qPCR)
An aliquot of 1 μg total RNA was reverse transcribed
into cDNA using PrimeScript™ RT reagent Kit with
gDNA Eraser (Takara: RR047A). The qPCR was then
carried out using SYBR® Premix Ex Tag™ II (Takara:
RR820A) in 20 μl reactions. All qRT-PCR reactions were
performed on ABI 7500 Real-Time PCR System (Applied
Biosystems, USA). Each sample was analyzed in tripli-
cate and the specificity of each PCR reaction was con-
firmed by melt curve analyses. The compliance of the
qPCR experiments with the MIQE (Minimum Informa-
tion for Publication of Quantitative Real-Time PCR Ex-
periments) guidelines was shown in the MIQE checklist
[44] (Additional file 9: Table S5). All the qPCR target in-
formation were listed in Additional file 10: Table S7.
Four house-keeper genes (GAPGH, TBP, β-actin and
HPRT1), which have been previously reported to be sta-
bly expressed in different human tissues or were once
used in ESCC qPCR study, were chosen as candidate en-
dogenous controls for the analysis of tissues and cells
lncRNA. RefFinder, a web-based comprehensive tool
(www.leonxie.com/referencegene.php), was then utilized
to evaluate and screen the optimal reference gene.
The expression levels of lncRNAs were calculated
using △Ct method, where △Ct = Cttarget – Ctreference,
smaller △Ct value indicates higher expression. Relative
expression of lncRNAs was calculated using 2–△△Ct method
normalized to endogenous control, with △Ct = Cttarget –
Ctreference, −△△Ct = − (sample △Ct – control △Ct).
All the primers used in the present study were listed in
the supporting information (Additional file 11: Table S6).Sequencing of qPCR products
After gel extraction and purification, the qPCR prod-
ucts were then cloned into the pUCm-T vector following
the manufacturer’s protocol (Sangon Biotech, Shanghai,
China), and then sequencing was performed by the
Sangon Biotech Co., Ltd.Additional files
Additional file 1: Table S1. Raw Ct values of 21 pairs of ESCC tumor
tissues and adjacent normal tissues.
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http://www.molecular-cancer.com/content/14/1/3Additional file 2: Table S2. Correlation between GAPDH level (raw Ct
value) in human plasma and clinicopathological factors of normal
controls and ESCC patients.
Additional file 3: Text S1. Supplementary data.
Additional file 4: Figure S1. Sequencing Results of Plasma qPCR
Products of POU3F3 (A), HNF1A-AS1 (B) and SPRY4-IT1 (C).
Additional file 5: Figure S2. Comparison plasma level of
ENST00000435885 and AFAP1-AS1 between ESCC and normal control
groups. ENST00000435885 (A) and AFAP1-AS1 (B) expression showed no
significant differences between ESCC and normal controls. Data
presented as △Ct values normalized to GAPDH.
Additional file 6: Figure S3. Effect of delayed processing of blood on
ESCC-related lncRNAs expression. ●, unfiltered plasma incubated at 4°C, △,
filtered plasma incubated at room temperature. The symbols represented
the means at specified time points.
Additional file 7: Table S3. Correlation between ESCC-related lncRNAs
expression (△Ct) in plasma and clinicopathological characteristics of 143
ESCC patients.
Additional file 8: Table S4. Clinical characteristics of study population.
Additional file 9: Table S5. Checklist MIQE.
Additional file 10: Table S7. qPCR target information.
Additional file 11: Table S6. Primers sequences.
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